Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non-Hodgkin lymphoma.
about
A comprehensive review of lenalidomide in B-cell non-Hodgkin lymphomaLymphoma Immunotherapy: Current StatusLenalidomide for the treatment of B-cell lymphoma.Expanding role of lenalidomide in hematologic malignanciesEx vivo antibody-dependent cellular cytotoxicity inducibility predicts efficacy of cetuximabEmerging therapies for the treatment of relapsed or refractory follicular lymphoma.Recent approaches of lipid-based delivery system for lymphatic targeting via oral route.New therapies in non-Hodgkin lymphoma.A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma.Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin LymphomaNovelties in the management of B-cell malignancies: B-cell receptor signaling inhibitors and lenalidomide.Chemotherapy and treatment algorithms for follicular lymphoma: a look at all options.The evolving role of lenalidomide in non-Hodgkin lymphoma.Clinical experience with lenalidomide alone or in combination with rituximab in indolent B-cell and mantle cell lymphomas.Obinutuzumab for the treatment of indolent lymphomaThe IL-15-Based ALT-803 Complex Enhances FcγRIIIa-Triggered NK Cell Responses and In Vivo Clearance of B Cell Lymphomas.Targeting indolent non-Hodgkin lymphoma.Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience.A phase II study of oxaliplatin and prednisone for patients with relapsed or refractory marginal zone lymphoma: Consortium for Improving Survival of Lymphoma trial.Lenalidomide in non-Hodgkin lymphoma: biological perspectives and therapeutic opportunities.Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: final results of a phase II study conducted by the Fondazione Italiana Linfomi.Phase II Study of Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BCNU, Etoposide, Cytarabine, and Melphalan for Non-Hodgkin Lymphoma: The Role of Histology.A phase 2 study of lenalidomide, rituximab, cyclophosphamide, and dexamethasone (LR-CD) for untreated low-grade non-Hodgkin lymphoma requiring therapy.The evolving role of targeted biological agents in the management of indolent B-cell lymphomas.The efficacy of lenalidomide combination therapy in heavily pretreated non-Hodgkin lymphoma patients: an Italian observational, multicenter, retrospective study.
P2860
Q26738937-F9E1547F-9A8F-430B-A567-356EC545A76EQ26782902-352E7B06-6468-4E88-B4E1-35B36DE36869Q30249007-B75550F4-F5A1-4137-951F-EB9F2DCC3258Q35592305-361562B7-E99C-4BD9-8EC1-7D6BFA879719Q36377940-18278772-9247-4776-92C4-7BC5468CFC41Q37524930-4793C371-E4E7-4681-B214-04DEF049DA56Q38242314-7B0DFD1C-843E-4AC2-8E03-74B8657E0EAEQ38315779-990948D4-E8C7-42C8-8FA3-5BEDF6F8263CQ38364912-7835D721-1DBD-4637-A36B-A2E7B99D4563Q38551337-2331A482-3A2C-417D-974C-9F9F6EC610C1Q38594364-7919C62C-0A9F-4C5F-8B07-1BAFD7D545B5Q38594531-9107B94D-2B38-4427-B05B-948B1FADFA85Q38744704-234DE703-A84E-4E7E-A308-DF0128227DA8Q38800049-020F984D-1CC7-4E52-B068-F5B92A4DAC90Q38818380-82FBEA2F-1C4F-4B68-9B5A-FDA868F7D06CQ38831202-81632B2A-47DD-449E-981B-22F1F3CFA0DDQ38917848-1487CCFB-7A54-4812-A247-C2A72B62B73CQ39138108-06964B94-D8F4-4942-823F-49FEA1C21140Q41298970-5B0BBC79-D879-459E-9E43-5AA0DC0543BDQ42087653-1836692E-91C2-4FC8-AAE4-9243ECA2BF8BQ42399897-B9616430-4102-49E3-9C91-A935C0C0FEF5Q46602218-4FA9BCC3-5BCE-487E-9DCF-1CA1296251F1Q48204093-749AEECB-F2CA-4022-985B-D6BB96DEA690Q49226138-64FFE20F-5577-42C9-8462-F481B3B42FECQ54083100-506B2B9A-B778-4102-A5D6-85992D272946
P2860
Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non-Hodgkin lymphoma.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Lenalidomide plus rituximab ca ...... indolent non-Hodgkin lymphoma.
@en
Lenalidomide plus rituximab ca ...... indolent non-Hodgkin lymphoma.
@nl
type
label
Lenalidomide plus rituximab ca ...... indolent non-Hodgkin lymphoma.
@en
Lenalidomide plus rituximab ca ...... indolent non-Hodgkin lymphoma.
@nl
prefLabel
Lenalidomide plus rituximab ca ...... indolent non-Hodgkin lymphoma.
@en
Lenalidomide plus rituximab ca ...... indolent non-Hodgkin lymphoma.
@nl
P2093
P2860
P356
P1476
Lenalidomide plus rituximab ca ...... indolent non-Hodgkin lymphoma.
@en
P2093
Ann Brunson
Christine Reed-Pease
Jeanna Welborn
Joseph M Tuscano
Karen Chee
Mehrdad Abedi
Mrinal Dutia
Robert T O'Donnell
P2860
P304
P356
10.1111/BJH.12755
P407
P577
2014-03-07T00:00:00Z